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Abstract
We conducted genome-wide association studies of three phenotypes: subjective well-being (N = 
298,420), depressive symptoms (N = 161,460), and neuroticism (N = 170,910). We identified three 
variants associated with subjective well-being, two with depressive symptoms, and eleven with 
neuroticism, including two inversion polymorphisms. The two depressive symptoms loci replicate 
in an independent depression sample. Joint analyses that exploit the high genetic correlations 
between the phenotypes (|ρ̂| ≈ 0.8) strengthen the overall credibility of the findings, and allow us 
to identify additional variants. Across our phenotypes, loci regulating expression in central 
nervous system and adrenal/pancreas tissues are strongly enriched for association.
 INTRODUCTION
Subjective well-being—as measured by survey questions on life satisfaction, positive affect, 
or happiness—is a major topic of research within psychology, economics, and epidemiology. 
Twin studies have found that subjective well-being is genetically correlated with depression 
(characterized by negative affect, anxiety, low energy, bodily aches and pains, pessimism, 
and other symptoms) and neuroticism (a personality trait characterized by easily 
experiencing negative emotions such as anxiety and fear)1–3. Depression and neuroticism 
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
CORRESPONDING AUTHORS: Daniel Benjamin (djbenjam@usc.edu) or Meike Bartels (m.bartels@vu.nl) or Philipp Koellinger 
(p.d.koellinger@vu.nl).
*These authors contributed equally
#Designed and oversaw the study.
URLs:
Genotype-Tissue Expression Portal www.GTExportal.org
Social Science Genetic Association Consortium (SSGAC) website: http://www.thessgac.org/#!data/kuzq8.
ACCESSION CODES: For neuroticism and depressive symptoms, we provide meta-analysis results from the combined analyses for 
all variants. For subjective well-being, meta-analysis results for all variants are provided for the full sample excluding 23andMe, for 
which only up to 10,000 SNPs can be reported. Therefore, for the subjective well-being meta-analysis, we provide results for 10,000 
SNPs. Meta-analysis results can be downloaded from the SSGAC website.
AUTHOR CONTRIBUTIONS: M.B., D.J.B., D.C., J.E.D.N., P.D.K., and R.F.K. designed and oversaw the study. A.O. and B.B. 
were responsible for quality control and meta-analyses. Bioinformatics analyses were carried out by J.B., T.E., M.A.F., J.R.G., J.L., 
S.F.W.M., M.N., and H.J.W. Other follow-up analyses were conducted by M.A.F., J.B., P.T., A.O., B.B., and R.K.L. Especially major 
contributions to the writing and editing were made by M.B., D.J.B., J.B., D.C., J.E.D.N., P.K., A.O., and P.T. All authors contributed 
to and critically reviewed the manuscript.
COMPETING FINANCIAL INTERESTS: The authors declare no competing financial interests.
HHS Public Access
Author manuscript
Nat Genet. Author manuscript; available in PMC 2016 October 18.
Published in final edited form as:
Nat Genet. 2016 June ; 48(6): 624–633. doi:10.1038/ng.3552.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
have received much more attention than subjective well-being in genetic-association studies, 
but the discovery of associated genetic variants with either of them has proven elusive4,5.
In this paper, we report a series of separate and joint analyses of subjective well-being, 
depressive symptoms, and neuroticism. Our primary analysis is a genome-wide association 
study (GWAS) of subjective well-being based on data from 59 cohorts (N = 298,420). This 
GWAS identifies three loci associated with subjective well-being at genome-wide 
significance (p < 5×10−8). We supplement this primary analysis with auxiliary GWAS meta-
analyses of depressive symptoms (N = 180,866) and neuroticism (N = 170,910), performed 
by combining publicly available summary statistics from published studies with new 
genome-wide analyses of additional data. In these auxiliary analyses we identify two loci 
associated with depressive symptoms and eleven with neuroticism, including two inversion 
polymorphisms. In depression data from an independent sample (N = 368,890), both 
depressive symptoms associations replicate (p = 0.004 and p = 0.015).
In our two joint analyses, we exploit the high genetic correlation between subjective well-
being, depressive symptoms, and neuroticism (i) to evaluate the credibility of the 16 
genome-wide significant associations across the three phenotypes, and (ii) to identify novel 
associations (beyond those identified by the GWAS). For (i), we investigate whether our 
three subjective well-being-associated SNPs “quasi-replicate” by testing them for 
association with depressive symptoms and neuroticism. We similarly examine the quasi-
replication record of the depressive symptoms and neuroticism loci by testing them for 
association with subjective well-being. We find that the quasi-replication record closely 
matches what would be expected given our statistical power if none of the genome-wide 
significant associations were chance findings. These results strengthen the credibility of 
(most of) the original associations. For (ii), we use a “proxy phenotype” approach6: we treat 
the set of loci associated with subjective well-being at p < 10−4 as candidates, and we test 
them for association with depressive symptoms and neuroticism. At the Bonferroni-adjusted 
0.05 significance threshold, we identify two loci associated with both depressive symptoms 
and neuroticism and another two associated with neuroticism.
In designing our study, we faced a tradeoff between analyzing a smaller sample with a 
homogeneous phenotype measure versus attaining a larger sample by jointly analyzing data 
from multiple cohorts with heterogeneous measures. For example, in our analysis of 
subjective well-being, we included measures of both life satisfaction and positive affect, 
even though these constructs are conceptually distinct7. In Supplementary Note and 
Supplementary Figure 1, we present a theoretical framework for evaluating the costs and 
benefits of pooling heterogeneous measures. In our context, given the high genetic 
correlation across measures, the framework predicts that pooling increases statistical power 
to detect variants. This prediction is supported by our results.
 RESULTS
 GWAS of subjective well-being
Following a pre-specified analysis plan, we conducted a sample-size-weighted meta-analysis 
(N = 298,420) of cohort-level GWAS summary statistics. The phenotype measure was life 
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satisfaction, positive affect, or (in some cohorts) a measure combining life satisfaction and 
positive affect. We confirmed previous findings9 of high pairwise genetic correlation 
between life satisfaction and positive affect using bivariate LD Score regression10 (ρ̂ = 0.981 
(SE = 0.065); Supplementary Table 1). Details on the 59 participating cohorts, their 
phenotype measures, genotyping, quality-control filters, and association models are provided 
in Online Methods, Supplementary Note, and Supplementary Tables 2–6.
As expected under polygenicity11, we observe inflation of the median test statistic (λGC = 
1.206). The estimated intercept from LD Score regression (1.012) suggests that nearly all of 
the inflation is due to polygenic signal rather than bias. We also performed family-based 
analyses that similarly suggest minimal confounding due to population stratification (Online 
Methods). Using a clumping procedure (Supplementary Note), we identified three 
approximately independent SNPs reaching genome-wide significance (“lead SNPs”). These 
three lead SNPs are indicated in the Manhattan plot (Figure 1a) and listed in Table 1. The 
SNPs have estimated effects in the range 0.015 to 0.018 standard deviations (SDs) per allele 
(each R2 ≈ 0.01%).
We also conducted separate meta-analyses of the components of our subjective well-being 
measure, life satisfaction (N = 166,205) and positive affect (N = 180,281) (Online Methods). 
Consistent with our theoretical conclusion that pooling heterogeneous measures increased 
power in our context, the life satisfaction and positive affect analyses yielded fewer signals 
across a range of p-value thresholds than our meta-analysis of subjective well-being 
(Supplementary Table 7).
 GWAS of depressive symptoms and neuroticism
We conducted auxiliary GWAS of depressive symptoms and neuroticism (see Online 
Methods, Supplementary Note, and Supplementary Tables 8–12 for details on cohorts, 
phenotype measures, genotyping, association models, and quality-control filters). For 
depressive symptoms (N = 180,866), we meta-analyzed publicly available results from a 
study performed by the Psychiatric Genomics Consortium (PGC)12 together with new 
results from analyses of the initial release of the UK Biobank data (UKB)13 and the 
Resource for Genetic Epidemiology Research on Aging (GERA) Cohort14. In UKB (N = 
105,739), we constructed a continuous phenotype measure by combining responses to two 
questions, which ask about the frequency in the past two weeks with which the respondent 
experienced feelings of unenthusiasm/disinterest and depression/hopelessness. The other 
cohorts had ascertained case-control data on major depressive disorder (GERA: Ncases = 
7,231, Ncontrols = 49,316; PGC: Ncases = 9,240, Ncontrols = 9,519).
For neuroticism (N = 170,910), we pooled summary statistics from a published study by the 
Genetics of Personality Consortium (GPC)4 with results from a new analysis of UKB data. 
The GPC (N = 63,661) harmonized different neuroticism batteries. In UKB (N = 107,245), 
our measure was the respondent’s score on a 12-item version of the Eysenck Personality 
Inventory Neuroticism scale15.
In both the depressive symptoms and neuroticism GWAS, the heterogeneous phenotypic 
measures are highly genetically correlated (Supplementary Table 1). As in our subjective 
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well-being analyses, there is substantial inflation of the median test statistics (λGC = 1.168 
for depressive symptoms, λGC = 1.317 for neuroticism), but the estimated LD Score 
intercepts (1.008 and 0.998, respectively) suggest that bias accounts for little or none of the 
inflation.
For depressive symptoms, we identified two lead SNPs, indicated in the Manhattan plot (Fig. 
1b). For neuroticism, our meta-analysis yielded 16 loci that are independent according to our 
locus definition (Fig. 1c). However, 6 of these reside within a well-known inversion 
polymorphism16 on chromosome 8. We established that all genome-wide significant signals 
in the inversion region are attributable to the inversion, and we confirmed that the inversion 
is associated with neuroticism in both of our neuroticism datasets, the GPC and the UKB 
(Online Methods and Supplementary Note). In our list of lead SNPs (Table 1), we only 
retain the most strongly associated SNP from these 6 loci to tag the chromosome 8 
inversion.
Another lead SNP associated with neuroticism, rs193236081, is located within a well-known 
inversion polymorphism on chromosome 17. We established that this association is 
attributable to the inversion polymorphism (Online Methods and Supplementary Note). 
Because this inversion yields only one significant locus and is genetically complex17, we 
hereafter simply use its lead SNP as its proxy. Our neuroticism GWAS therefore identified 
11 lead SNPs, two of which tag inversion polymorphisms. A concurrent neuroticism GWAS 
using a subset of our sample reports similar findings18.
As shown in Table 1, the estimated effects of all lead SNPs associated with depressive 
symptoms and neuroticism are in the range 0.020 to 0.031 SDs per allele (R2 0.02% to 
0.04%). In the UKB cohort we estimated the effect of an additional allele of the 
chromosome 8 inversion polymorphism itself on neuroticism to be 0.035 SDs 
(Supplementary Table 13). The inversion explains 0.06% of the variance in neuroticism 
(roughly the same as the total variance explained jointly by the 6 SNPs in the inversion 
region).
 Genetic overlap across subjective well-being, depressive symptoms, and neuroticism
Figure 2a shows that the three pairwise genetic correlations between our phenotypes, 
estimated using bivariate LD Score regression10, are substantial: −0.81 (SE = 0.046) 
between subjective well-being and depressive symptoms, −0.75 (SE = 0.034) between 
subjective well-being and neuroticism, and 0.75 (SE = 0.027) between depressive symptoms 
and neuroticism. Using height as a negative control, we also examined pairwise genetic 
correlations between each of our phenotypes and height and, as expected, found all three to 
be modest, e.g., 0.07 with subjective well-being (Supplementary Table 1). The high genetic 
correlations between subjective well-being, depressive symptoms, and neuroticism may 
suggest that the genetic influences on these phenotypes are predominantly related to 
processes common across the phenotypes, such as mood, rather than being phenotype-
specific.
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 Quasi-replication and Bayesian credibility analyses
We assessed the credibility of our findings using a standard Bayesian framework19,20 in 
which a positive fraction of SNPs have null effects and a positive fraction have non-null 
effects (Online Methods). For each phenotype, the non-null effect sizes are assumed to be 
drawn from a normal distribution whose variance is estimated from the GWAS summary 
statistics. As a first analysis, for each lead SNP’s association with its phenotype, we 
calculated the posterior probability of null association after having observed the GWAS 
results. We found that, for any assumption about the fraction of non-null SNPs in the range 
1% to 99%, the probability of true association always exceeds 95% for all 16 loci (and 
always exceeds 98% for 14 of them).
To further probe the credibility of the findings, we performed “quasi-replication” exercises 
(Online Methods) in which we tested the subjective well-being lead-SNPs for association 
with depressive symptoms and neuroticism. We similarly tested the depressive symptoms 
lead-SNPs and the neuroticism lead-SNPs for association with subjective well-being. Below, 
we refer to the phenotype for which the lead SNP was identified as the first-stage phenotype 
and the phenotype used for the quasi-replication as the second-stage phenotype. To avoid 
sample overlap, for each quasi-replication analysis we omitted any cohorts that contributed 
to the GWAS of the first-stage phenotype.
Results of the quasi-replication of the three subjective well-being lead-SNPs are shown in 
Figure 3a. For ease of interpretation, the reference allele for each association in the figure is 
chosen such that the predicted sign of the second-stage estimate is positive. We find that two 
out of the three subjective well-being lead-SNPs are significantly associated with depressive 
symptoms (p = 0.004 and p = 0.001) in the predicted direction. For neuroticism, where the 
second-stage sample size (N = 68,201) is about half as large, the subjective well-being-
increasing allele has the predicted sign for all three SNPs, but none reach significance.
Figures 3b and 3c show the results for the depressive symptoms and neuroticism lead-SNPs, 
respectively. In each panel, the blue crosses depict results from the quasi-replications where 
subjective well-being is the second-stage phenotype. We find that the two depressive 
symptoms lead-SNPs have the predicted sign for subjective well-being, and one is nominally 
significant (p = 0.04). Finally, of the eleven neuroticism lead-SNPs, nine have the predicted 
sign for subjective well-being. Four of the eleven are nominally significantly associated with 
subjective well-being, all with the predicted sign. One of the four is the SNP tagging the 
inversion on chromosome 816. That SNP’s association with neuroticism (and likely with 
subjective well-being) is driven by its correlation with the inversion (Supplementary Fig. 2).
To evaluate what these quasi-replication results imply about the credibility of the 16 GWAS 
associations, we compared the observed quasi-replication record to the quasi-replication 
record expected given our statistical power. We calculated statistical power using our 
Bayesian framework, under the hypothesis that each lead SNP has a non-null effect on both 
the first- and second-stage phenotypes. Our calculations take into account both the imperfect 
genetic correlation between the first- and second-stage phenotypes and inflation of the first-
stage estimates due to the well-known problem of winner’s curse (Online Methods). Of the 
19 quasi-replication tests, our calculations imply that 16.7 would be expected to yield the 
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anticipated sign and 6.9 would be significant at the 5% level. The observed numbers are 16 
and 7. Our quasi-replication results are thus consistent with the hypothesis that none of the 
16 genome-wide significant associations are chance findings, and in fact strengthen the 
credibility of our GWAS results (Supplementary Table 14).
 Lookup of depressive symptoms and neuroticism lead-SNPs
Investigators of an ongoing large-scale GWAS of major depressive disorder (N = 368,890) in 
the 23andMe cohort shared association results for the loci identified in our depressive 
symptoms and neuroticism analyses (Online Methods and Supplementary Table 15)21. 
Because the depression sample overlaps with our subjective well-being sample, we did not 
request a lookup of the subjective well-being-associated SNPs.
In Figures 3b and 3c, the results are depicted as green crosses. For interpretational ease, we 
chose the reference allele so that positive coefficients imply that the estimated effect is in the 
predicted direction. All 13 associations have the predicted sign. Of the 11 neuroticism 
polymorphisms, four are significantly associated with depression at the 5% level. Both of the 
depressive symptoms lead-SNPs replicate (p = 0.004 and p = 0.015), with effect sizes (0.007 
and −0.007 SDs per allele), close to those predicted by our Bayesian framework (0.008 and 
−0.006) (Supplementary Table 14 and Supplementary Table 15).
Panel A of Table 1 summarizes the results for the 16 lead SNPs identified across our 
separate GWA analyses of the three phenotypes. The right-most column summarizes the 
statistical significance of the quasi-replication and depression lookup analyses of each SNP.
 Proxy-phenotype analyses
To identify additional SNPs associated with depressive symptoms, we conducted a two-stage 
“proxy phenotype” analysis (Online Methods). In the first stage, we ran a new GWAS of 
subjective well-being to identify a set of candidate SNPs. Specifically, from each locus 
exhibiting suggestive evidence of association (p < 10−4) with subjective well-being, we 
retained the SNP with the lowest p-value as a candidate. In the second stage, we tested these 
candidates for association with depressive symptoms at the 5% significance threshold, 
Bonferroni-adjusted for the number of candidates. We used an analogous two-stage 
procedure to identify additional SNPs associated with neuroticism. The first-stage subjective 
well-being sample differs across the two proxy-phenotype analyses (and from the primary 
subjective well-being GWAS sample) because we assigned cohorts across the first and 
second stages so as to maximize statistical power for the overall procedure.
For depressive symptoms, there are 163 candidate SNPs. 115 of them (71%) have the 
predicted direction of effect on depressive symptoms, 20 are significantly associated at the 
5% significance level (19 in the predicted direction), and two remain significant after 
Bonferroni adjustment. For neuroticism, there are 170 candidate SNPs. 129 of them (76%) 
have the predicted direction of effect, all 28 SNPs significant at the 5% level have the 
predicted sign, and four of these remain significant after Bonferroni adjustment 
(Supplementary Fig. 3 and Supplementary Tables 16 and 17). Two of the four are the SNPs 
identified in the proxy-phenotype analysis for depressive symptoms.
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Table 1 lists the four SNPs in total identified by the proxy-phenotype analyses.
 Biological analyses
To shed some light on possible biological mechanisms underlying our findings, we 
conducted several analyses.
We began by using bivariate LD Score regression10 to quantify the amount of genetic 
overlap between each of our three phenotypes and ten neuropsychiatric and physical health 
phenotypes. Figures 2b and c display the estimates for subjective well-being and the 
negative of the estimates for depressive symptoms and neuroticism (since subjective well-
being is negatively genetically correlated with depressive symptoms and neuroticism). 
Subjective well-being, depressive symptoms, and neuroticism have strikingly similar 
patterns of pairwise genetic correlation with the other phenotypes.
Figure 2b shows the results for the five neuropsychiatric phenotypes we examined: 
Alzheimer’s disease, anxiety disorders, autism spectrum disorder, bipolar disorder, and 
schizophrenia. For four of these phenotypes, genetic correlations with depression (but not 
neuroticism or subjective well-being) were reported in Bulik-Sullivan et al.10. For 
schizophrenia and bipolar disorder, our estimated correlations with depressive symptoms, 
0.33 and 0.26, are substantially lower than Bulik-Sullivan et al.’s point estimates but 
contained within their 95% confidence intervals. By far the largest genetic correlations we 
estimate are with anxiety disorders: −0.73 with subjective well-being, 0.88 with depressive 
symptoms, and 0.86 with neuroticism. Genetic correlations estimated from GWAS data have 
not been previously reported for anxiety disorders.
Figure 2c shows the results for five physical health phenotypes that are known or believed to 
be risk factors for various adverse health outcomes: body mass index (BMI), ever-smoker 
status, coronary artery disease, fasting glucose, and triglycerides. The estimated genetic 
correlations are all small in magnitude, consistent with earlier work, although the greater 
precision of our estimates allows us to reject null effects in most cases. The signs are 
generally consistent with those of the phenotypic correlations reported in earlier work 
between our phenotypes and outcomes such as obesity22, smoking23,24, and cardiovascular 
health25.
Next, to investigate whether our GWAS results are enriched in particular functional 
categories, we applied stratified LD Score regression26 to our meta-analysis results. In our 
first analysis, we report estimates for all 53 functional categories included in the “baseline 
model”; the results for subjective well-being, depressive symptoms, and neuroticism are 
broadly similar (Supplementary Tables 18–20) and are in line with what has been found for 
other phenotypes26. In our second analysis, the categories are groupings of SNPs likely to 
regulate gene expression in cells of a specific tissue. The estimates for subjective well-being, 
depressive symptoms, and neuroticism are shown in Figure 4a, alongside height, which is 
again included as a benchmark27 (see also Supplementary Table 21).
We found significant enrichment of CENTRAL NERVOUS SYSTEM for all three 
phenotypes and, perhaps more surprisingly, enrichment of ADRENAL/PANCREAS for 
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subjective well-being and depressive symptoms. The cause of the ADRENAL/PANCREAS 
enrichment is unclear, but we note that the adrenal glands produce several hormones, 
including cortisol, epinephrine, and norepinephrine, known to play important roles in the 
bodily regulation of mood and stress. It has been robustly found that blood serum levels of 
cortisol in patients afflicted by depression are elevated relative to controls28.
While the above analyses utilize the genome-wide data, we also conducted three analyses 
(Online Methods) restricted to the 16 GWAS and four proxy-phenotype SNPs in Table 1. In 
brief, we ascertained whether each SNP (or a variant in strong linkage disequilibrium (LD) 
with it) falls into any of the following three classes: (i) resides in a locus for which genome-
wide significant associations with other phenotypes have been reported (Supplementary 
Table 22), (ii) is nonsynonymous (Supplementary Table 23), and (iii) is an eQTL in blood or 
in one of 14 other tissues (although the non-blood analyses are based on smaller samples) 
(Supplementary Table 24). Here we highlight a few particularly interesting results.
We found that five of the 20 SNPs are in loci in which genome-wide significant associations 
have previously been reported. Two of these five are schizophrenia loci. Interestingly, one of 
them harbors the gene DRD2, which encodes the D2 subtype of the dopamine receptor, a 
target for antipsychotic drugs29 that is also known to play a key role in neural reward 
pathways30. Motivated by these findings, as well as by the modest genetic correlations with 
schizophrenia reported in Figure 2b, we examined whether the SNPs identified in a recent 
study of schizophrenia31 are enriched for association with neuroticism in our non-
overlapping UKB sample (N = 107,245). We conducted several tests and found strong 
evidence of such enrichment (Supplementary Note). For example, we found that the p-values 
of the schizophrenia SNPs tend to be much lower than the p-values of a randomly selected 
set of SNPs matched on allele frequency (p = 6.50×10−71).
Perhaps the most notable pattern that emerges from our biological analyses is that the 
inversions on chromosomes 8 and 17 are implicated consistently across all analyses. The 
inversion-tagging SNP on chromosome 8 is in LD with SNPs that have previously been 
found to be associated with BMI32 and triglycerides33 (Supplementary Table 22). We also 
conducted eQTL analyses in blood for the inversion itself and found that it is a significant 
cis-eQTL for 7 genes (Supplementary Table 24). As shown in Figure 4b, all 7 genes are 
positioned in close proximity to the inversion breakpoints, suggesting that the molecular 
mechanism underlying the inversion’s effect on neuroticism could involve the relocation of 
regulatory sequences. Two of the genes (MSRA, MTMR9) are known to be highly expressed 
in tissues and cell types that belong to the nervous system, and two (BLK, MFHAS1) in the 
immune system. In the tissue-specific analyses, we found that the SNP tagging the inversion 
is a significant eQTL for two genes, AF131215.9 (in tibial nerve and thyroid tissue analyses) 
and NEIL2 (tibial nerve tissue), both of which are also located near the inversion breakpoint.
The SNP tagging the chromosome 17 inversion is a significant cis-eQTL for five genes in 
blood and is an eQTL in all 14 other tissues (Supplementary Table 24). It alone accounts for 
151 out of the 169 significant associations identified in the 14 tissue-specific analyses. 
Additionally, the SNP is in near-perfect LD (R2 > 0.97) with 11 missense variants 
(Supplementary Table 23) in three different genes, one of which is MAPT. MAPT, which is 
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also implicated in both the blood and the other tissue-specific analyses, encodes a protein 
important in the stabilization of microtubules in neurons. Associations have been previously 
reported between SNPs in MAPT (all of which are in strong LD with our inversion-tagging 
SNP) and neurodegenerative disorders, including Parkinson’s disease34 and progressive 
supranuclear palsy35, a rare disease whose symptoms include depression and apathy.
 DISCUSSION
The discovery of genetic loci associated with subjective well-being, depression, and 
neuroticism has proven elusive. Our study identified several credible associations for two 
main reasons. First, our analyses had greater statistical power than prior studies because ours 
were conducted in larger samples. Our GWAS findings—three loci associated with 
subjective well-being, two with depressive symptoms, and eleven with neuroticism—support 
the view that GWAS can successfully identify genetic associations with highly polygenic 
phenotypes in sufficiently large samples5,36. A striking finding is that two of our identified 
associations are with inversion polymorphisms.
Second, our proxy-phenotype analyses further boosted power by exploiting the strong 
genetic overlap between our three phenotypes. These analyses identified two additional loci 
associated with neuroticism and two with both depressive symptoms and neuroticism. 
Through our quasi-replication tests, we also demonstrated how studying genetically 
overlapping phenotypes in concert can provide evidence on the credibility of GWAS 
findings. Our direct replication of the two genome-wide significant associations with 
depressive symptoms in an independent depression sample provides further confirmation of 
those findings (Fig. 2b and Supplementary Table 15).
We were able to assemble much larger samples than prior work in part because we combined 
data across heterogeneous phenotype measures. Our results reinforce the conclusions from 
our theoretical analysis that doing so increased our statistical power, but our strategy also has 
drawbacks. One is that mixing different measures may make any discovered associations 
more difficult to interpret. Research studying higher quality measures of the various facets of 
subjective well-being, depressive symptoms, and neuroticism is a critical next step. Our 
results can help facilitate such work because if the variants we identify are used as 
candidates, studies conducted in the smaller samples in which more fine-grained phenotype 
measures are available can be well powered.
Another limitation of mixing different measures is that doing so may reduce the heritability 
of the resulting phenotype, if the measures are influenced by different genetic factors. 
Indeed, our estimates of SNP-based heritability10 for our three phenotypes are quite low: 
0.040 (SE = 0.002) for subjective well-being, 0.047 (SE = 0.004) for depressive symptoms, 
and 0.091 (SE = 0.007) for neuroticism. We correspondingly find that polygenic scores 
constructed from all measured SNPs explain a low fraction of variance in independent 
samples: ~0.9% for subjective well-being, ~0.5% for depressive symptoms, and ~0.7% for 
neuroticism (Online Methods). The low heritabilities imply that even when polygenic scores 
can be estimated using much larger samples than ours, they are unlikely to attain enough 
predictive power to be clinically useful.
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According to our Bayesian calculations, the true explanatory power (corrected for winner’s 
curse) of the SNP with the largest posterior R2 is 0.003% for subjective well-being, 0.002% 
for depressive symptoms, and 0.011% for neuroticism (Supplementary Table 14). These 
effect sizes imply that in order to account for even a moderate share of the heritability, 
hundreds or (more likely) thousands of variants will be required. They also imply that our 
study’s power to detect variants of these effect sizes was not high—for example, our 
statistical power to detect the lead SNP with largest posterior R2 was only ~13%—which in 
turn means it is likely that there exist many variants with effect sizes comparable to our 
identified SNPs that evaded detection. These estimates suggest that many more loci will be 
found in studies with sample sizes realistically attainable in the near future. Consistent with 
this projection, when we meta-analyze the 54 SNPs reaching p < 10−5 in our analyses of 
depressive symptoms together with the 23andMe replication sample for depression, the 
number of genome-wide significant associations rises from 2 to 5 (Supplementary Table 15).
 ONLINE METHODS
This article is accompanied by a Supplementary Note with further details.
 GWAS of subjective well-being
Genome-wide association analyses were performed at the cohort level according to a pre-
specified analysis plan. Genotyping was performed using a range of common, commercially 
available genotyping arrays. The analysis plan instructed cohorts to upload results imputed 
using the HapMap2 CEU (r22.b36) reference sample37. We meta-analyzed summary 
association statistics from 59 contributing cohorts with a combined sample size of 298,420 
individuals. Before meta-analysis, a uniform set of quality-control (QC) procedures were 
applied to the cohort-level summary statistics, including but not limited to the EasyQC38 
protocol. All analyses were restricted to European-ancestry individuals.
We performed a sample-size-weighted meta-analysis of the cohort-level summary statistics. 
To adjust standard errors for non-independence, we inflated them using the square root of 
the estimated intercept from a LD Score regression10. We also performed secondary, 
separate meta-analyses of positive affect (N = 180,281) and life satisfaction (N = 166,205) 
and a post hoc genome-wide analysis of subjective well-being in cohorts with 1000G-
imputed data (N = 229,883); see Supplementary Figures 4–6.
Detailed cohort descriptions, information about cohort-level genotyping and imputation 
procedures, cohort-level measures, and quality-control filters are shown in Supplementary 
Tables 2–6. Supplementary Table 7 reports association results from the following four meta-
analyses: the primary subjective well-being analysis, the life satisfaction analysis, the 
positive affect analysis, and the post hoc subjective well-being analysis. For each phenotype, 
we provide association results for the set of approximately independent SNPs that attained a 
p-value smaller than 10−5. We identify these SNP using the same clumping algorithm as for 
the lead SNPs, but with the p-value threshold set at 10−5 instead of genome-wide 
significance.
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 GWAS of depressive symptoms and neuroticism
Our auxiliary genome-wide association studies of DS and neuroticism were conducted in 
1000G-imputed data, combining new genome-wide association analyses with publicly 
available summary statistics from previously published studies. We applied a similar QC 
protocol to that used in our primary subjective well-being analysis. In the DS meta-analysis 
(N = 180,866), we weighted the UKB analysis by sample size and the two case-control 
studies by effective sample size. In the neuroticism meta-analysis, we performed a sample-
size-weighted fixed-effects meta-analysis of the UKB data and the publicly available 
summary statistics from a previous GWAS of neuroticism.
Detailed cohort descriptions, information about cohort-level genotyping and imputation 
procedures and quality-control filters are provided in Supplementary Tables 8–12. See 
Supplementary Figure 7 for quantile-quantile plots of the neuroticism and DS meta-analysis 
results. Association results for the set of approximately independent set of SNPs that 
attained a p-value smaller than 10−5 are supplied in Supplementary Table 25.
 Population stratification
To quantify the fraction of the observed inflation of the mean test statistic that is due to bias, 
we used LD Score regression10. The estimated LD Score regression intercepts were all close 
to 1, suggesting no appreciable inflation of the test statistics attributable to population 
stratification in any of our subjective well-being, depressive symptoms, or neuroticism meta-
analyses (Supplementary Fig. 8). For all three phenotypes, our estimates suggest that less 
than 2% of the observed inflation of the mean test statistic was accounted for by bias.
In our primary GWAS of subjective well-being, we also used two family-based analyses to 
test for and quantify stratification biases. These analyses used within-family (WF) estimates, 
the coefficients from regressing the difference in phenotype across siblings on the difference 
in siblings’ genotype (and controls). These WF estimates are not biased by population 
stratification because siblings share their ancestry entirely, and therefore differences in 
siblings’ genotypes cannot be due to the siblings being from different population groups. We 
meta-analyzed association statistics from WF analyses conducted in four cohorts.
In the first analysis, we estimated the fraction of SNPs for which the signs of the WF 
estimates were concordant with the signs of the estimates obtained from a GWAS identical 
to our primary subjective well-being GWAS except with the four family cohorts excluded. 
For the 112,884 approximately independent SNPs considered, we found a sign concordance 
of 50.83%, which is significantly greater than 50% (p = 1.04 × 10−8). Under the null 
hypothesis of no population stratification, the observed sign concordance matches the 
expected rate after winner’s curse adjustment nearly perfectly, 50.83% (Supplementary Fig 
9).
The second analysis utilized the WF regression coefficient estimates (i.e., not only their 
signs) to estimate the amount of stratification bias. For each SNP j, let βj denote the GWAS 
estimate, and let βWF,j denote the WF estimate. Under the assumption that the causal effect 
of each SNP is the same within families as in the population, we can decompose the 
estimates as:
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where βj is the true underlying GWAS parameter for SNP j, sj is the bias due to stratification 
(defined to be orthogonal to βj and Uj), and Uj and Vj are the sampling variances of the 
estimates with E(Uj)=E(Vj)=0. Whenever sj ≠ 0, the GWAS estimate of β̂j is biased away 
from the population parameter βj. The proportion of variance in the GWAS coefficients 
accounted for by true genetic signals can be written as:
In Supplementary Note, we show that with estimates β̂j and β̂WF,j (and their standard errors) 
from independent samples, it is possible to consistently estimate the above ratio. The 95% 
confidence interval for the ratio implies that between 72% and 100% of the signal in the 
GWAS estimates is a result of true genetic effects on subjective well-being rather than 
stratification.
 Analyses of inversion polymorphisms
Two genome-wide significant SNPs for the neuroticism analysis are located within well-
known inversion polymorphisms, on chromosomes 8 and 17. Using the genotypic data 
available for UKB participants, we called the inversion genotypes for UKB participants 
using a PCA-mixture method. For both inversions, the method clearly distinguishes 3 
clusters of genotypes, corresponding to inversion genotypes (Supplementary Fig. 10). We 
validated the PCA-mixture procedure using existing methods designed to call inversion 
genotypes39 (Supplementary Table 26).
For both inversions, we established that the inversion-tagging SNPs were always located in 
close proximity of the inversion region (Fig. 3b and Supplementary Figs. 10–11). 
Supplementary Tables 27–28 list the twenty variants that most strongly correlate with the 
PCs that capture the inversion polymorphisms on chromosome 8 and 17, respectively. In 
additional analyses, we confirmed that the inversion is associated with neuroticism and 
subjective well-being in independent cohorts (Supplementary Tables 29–30 and 
Supplementary Fig. 12–13).
 Proxy-phenotype analyses
In these analyses, we used a two-stage approach that has been successfully applied in other 
contexts6. In the first stage, we conducted a meta-analysis of our first-stage “proxy 
phenotype” and used our clumping procedure to identify the set of approximately 
independent SNPs at the p-value threshold of 10−4. In the second stage, we tested SNPs 
identified in stage 1 (or high-LD proxies for them) for association with a second-stage 
phenotype in an independent (non-overlapping) sample. In our analyses, we used our 
primary phenotype of subjective well-being as the proxy-phenotype. We conducted one 
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analysis with depressive symptoms as the second-stage phenotype, and one analysis with 
neuroticism as the second-stage phenotype. In the analyses, we omit cohorts from the first-
stage or second-stage as needed to ensure that the samples in the two stages are non-
overlapping. Supplementary Table 31 lists the cohort restrictions imposed. These cohort 
restrictions, as well as the p-value threshold of 10−4, were chosen before the data were 
analyzed on the basis of statistical power calculations.
To test for cross-phenotype enrichment, we used a non-parametric procedure that tests 
whether the lead SNPs are more strongly associated with the second-stage phenotype than 
randomly chosen sets of SNPs with a similar distribution of allele frequencies 
(Supplementary Note).
To test the individual lead SNPs for experiment-wide significance, we examined whether 
any of the lead SNPs (or their high-LD proxies) are significantly associated with the second-
stage phenotype at the Bonferroni-adjusted significance level of 0.05/Y.
 Genetic correlations
We used bivariate LD Score regression10 to quantify the amount of genetic heterogeneity 
among the phenotypic measures pooled in each of our three separate meta-analyses. For 
subjective well-being, we estimated a pairwise correlation of 0.981 (SE = 0.065) between 
life satisfaction and positive affect, 0.897 (SE = 0.017) between “wellbeing” (our measure 
that combines life satisfaction and positive affect) and life satisfaction, and 1.031 (SE = 
0.019) between positive affect and wellbeing. For depressive symptoms, we estimated a 
genetic correlation of 0.588 (SE = 0.242) between GERA and PGC, 0.972 (SE = 0.216) 
between GERA and UKB, and 0.797 (SE = 0.108) between UKB and PGC. Finally, we 
estimated a genetic correlation of 1.11 (SE = 0.14) between the measures of neuroticism in 
the UKB analyses and the summary statistics from a previously published meta-analysis4.
 Bayesian credibility analyses
To evaluate the credibility of our findings, we use a standard Bayesian framework19 in which 
our prior distribution for any SNP’s effect is:
Here, π is the fraction of non-null SNPs, and  is the variance of the non-null SNPs for trait 
j ∈ {subjective well-being, depressive symptoms, neuroticism}. In this framework, 
credibility is defined as the probability that a given SNP is non-null.
We begin with univariate analyses of the GWAS results that do not incorporate the additional 
information from the quasi-replication analyses of the 16 lead SNPs reported in Table 1. We 
use the three subjective well-being-associated SNPs to illustrate our approach, but we use 
analogous procedures when analyzing depressive symptoms and neuroticism. We calculate 
credibility for each value π ∈ 0.01,0.02,…,0.99. For each assumed value of π, we estimate 
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 by maximum likelihood (Supplementary Note). For each SNP, we use Bayes’ rule to 
obtain a posterior estimate of credibility for each of the assumed values of π. Supplementary 
Figure 14 shows that for all considered values of π and all three SNPs, the posterior 
probability that the SNP is null is below 1%. Similar analyses of the depressive symptoms 
and neuroticism SNPs show that the posterior probability never exceeds 5%.
In our joint analyses, we consider two phenotypes with genetic correlation rg. We make the 
simplifying assumption that the set of null SNPs is the same for both phenotypes. The joint 
distribution of a SNP’s effect on the two phenotypes is then given by
With coefficient estimates, β̂1 and β̂2, obtained from non-overlapping samples, the variance-
covariance matrix of the estimation error will be diagonal. We denote the diagonal entries of 
this matrix, which represent the variances of the estimation error in the two samples, by 
and . This gives us the joint prior distribution
To select parameter values for the prior, we use the estimates of rg reported in 
Supplementary Table 1, and we estimate the parameters π, , and  from GWAS summary 
statistics using a maximum likelihood procedure. For this procedure, we make the standard 
assumption10,40 that the variance of a SNP’s effect size is inversely proportional to the 
variance of its genotype, 2×MAF×(1−MAF).
The credibility estimates follow from applying Bayes’ Rule to calculate either the 
probability that the SNP is non-null (an event denoted C) given only the first-stage estimate, 
P(C|β̂1), or the probability that the SNP is non-null conditional on the results of both the 
first-stage GWAS and the quasi-replication analysis, P(C|β̂1, β̂2). Credibility estimates for 
our lead SNPs are in Supplementary Table 14.
To calculate the expected record of a replication or quasi-replication study, we assume that 
the SNP is non-null for both phenotypes. (This is analogous to a standard power calculation 
for a single phenotype, in which the SNP is assumed to be non-null.) Under this assumption, 
β̂1 and β̂2 are jointly normally distributed, implying that the conditional distribution of β̂2 
given β̂1 is
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Using this equation, we can calculate the probability that the GWAS estimates will have 
concordant signs across the two phenotypes, or that the GWAS estimate of the second-stage 
phenotype will reach some level of significance. These probabilities can be summed over the 
set of lead SNPs to generate the expected number of SNPs meeting the criterion.
To obtain effect-size estimates for a SNP that are adjusted for the winner’s curse 
(Supplementary Table 32), we use the mean of the posterior distribution of the SNP’s effect, 
conditional on the quasi-replication result and the SNP being non-null. We derive the 
posterior distribution and expected R2 in the Supplementary Note.
 Lookup of depressive symptoms and neuroticism-associated SNPs in an independent 
depression study
We partnered with the investigators of an ongoing large-scale GWAS of major depressive 
symptoms (N = 368,890) to follow up on the associations identified in the depressive 
symptoms and neuroticism analyses. The participants of the study were all European-
ancestry customers of 23andMe, a personal genomics company, who responded to online 
survey questions about mental health. We did not request results for the SNPs identified in 
the subjective well-being or proxy-phenotype analyses, since these were both conducted in 
samples that overlap with 23andMe’s depression sample. For details on association models, 
quality-control filters, and the ascertainment of depression status, we refer to the companion 
study21. The p-values we report are based on standard errors that have been inflated by the 
square by the intercept from an LD score regression10.
 Polygenic prediction
To evaluate the predictive power of a polygenic score derived from the subjective well-being 
meta-analysis results, we used two independent hold-out cohorts: the Health and Retirement 
Study (HRS41) and the Netherlands Twin Register (NTR42,43). To generate the weights for 
the polygenic score, we performed meta-analyses of the pooled subjective well-being 
phenotype excluding each of the holdout cohorts, applying a minimum-sample-size filter of 
100,000 individuals (Supplementary Note). The results from these analyses are reported in 
Supplementary Table 33 and depicted in Supplementary Figure 15.
 Biological annotation
For the biological annotation of the 20 SNPs in Table 1, we generated a list of LD partners 
for each of the original SNPs. A SNP was considered an LD partner for the original SNP if 
(i) its pairwise LD with the original SNP exceeded R2 = 0.6 and (ii) it was located within 
250kb of the original SNP. We also generated a list of genes residing within loci tagged by 
our lead SNPs (Supplementary Table 34).
We used the NHGRI GWAS catalog44 to determine which of our 20 SNPs (and their LD 
partners) were in LD with SNPs for which genome-wide significant associations have been 
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previously reported. Since the GWAS catalog does not always include the most recent 
GWAS results available, we included additional recent GWAS studies. We used the tool 
HaploReg45 to identify nonsynonymous variants in LD with any of the 20 SNPs or their LD 
partners.
We examined whether the 20 polymorphisms in Table 1 were associated with gene 
expression levels (Supplementary Table 24 and Supplementary Note). The cis-eQTL 
associations were performed in 4,896 peripheral-blood gene expression and genome-wide 
SNP samples from two Dutch cohorts measured on the Affymetrix U219 platform42,43,46. 
We also performed eQTL lookups of our 20 SNPs in the Genotype-Tissue Expression 
Portal47,48. We restricted the search to the following trait-relevant tissues: hippocampus, 
hypothalamus, anterior cingulate cortex (BA24), putamen (basal ganglia), frontal cortex 
(BA9), nucleus accumbens (basal ganglia), caudate (basal ganglia), cortex, cerebellar 
hemisphere, cerebellum, tibial nerve, thyroid, adrenal gland, and pituitary.
Finally, using a gene co-expression database49, we explored the predicted functions of genes 
co-locating with the 20 SNPs in Table 1 (Supplementary Table 35).
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Manhattan plots of GWAS results
(a) Subjective well-being (N = 298,420), (b) Depressive symptoms (N = 180,866), (c) 
Neuroticism (N = 170,911). The x-axis is chromosomal position, and the y-axis is the 
significance on a −log10 scale. The upper dashed line marks the threshold for genome-wide 
significance (p = 5×10 8); the lower line marks the threshold for nominal significance (p = 
10 5). Each approximately independent genome-wide significant association (“lead SNP”) is 
marked by ×. Each lead SNP is the lowest p-value SNP within the locus, as defined by our 
clumping algorithm (Supplementary Note).
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Fig. 2. Genetic correlations with bars representing 95% confidence intervals
The correlations are estimated using bivariate LD Score (LDSC) regression. (a) Genetic 
correlations between subjective well-being, depressive symptoms, and neuroticism (“our 
three phenotypes”), as well as between our three phenotypes and height. (b) Genetic 
correlations between our three phenotypes and selected neuropsychiatric phenotypes. (c) 
Genetic correlations between our three phenotypes and selected physical health phenotypes. 
In (b) and (c), we report the negative of the estimated correlation with depressive symptoms 
and neuroticism (but not subjective well-being).
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Fig. 3. Quasi-replication and lookup of lead SNPs
In quasi-replication analyses, we examined whether (a) lead SNPs identified in the 
subjective well-being meta-analyses are associated with depressive symptoms or 
neuroticism, (b) lead SNPs identified in the analyses of depressive symptoms are associated 
with subjective well-being, and (c) lead SNPs identified in the analyses of neuroticism are 
associated with subjective well-being. The quasi-replication sample is always restricted to 
non-overlapping cohorts. In a separate lookup exercise, we examined whether lead SNPs for 
depressive symptoms and neuroticism are associated with depression in an independent 
sample of 23andMe customers (N = 368,890). The results from this lookup are depicted as 
green crosses in (b) and (c). Bars represent 95% CIs (not adjusted for multiple testing). For 
interpretational ease, we choose the reference allele so that positive coefficients imply that 
the estimated effect is in the predicted direction. Listed below each lead SNP is the nearest 
gene.
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Fig. 4. Results from selected biological analyses
(a) Estimates of the expected increase in the phenotypic variance accounted for by a SNP 
due to the SNP’s being in a given category (τc), divided by the LD Score heritability of the 
phenotype (h2). Each estimate of τc comes from a separate stratified LD Score regression, 
controlling for the 52 functional annotation categories in the “baseline model.” The bars 
represent 95% CIs (not adjusted for multiple testing). To benchmark the estimates, we 
compare them to those obtained from a recent study of height27. (b) Inversion polymorphism 
on chromosome 8 and the 7 genes for which the inversion is a significant cis-eQTL at FDR 
< 0.05. The upper half of the figure shows the Manhattan plot for neuroticism for the 
inversion and surrounding regions. The bottom half shows the squared correlation between 
the SNPs and the principal component that captures the inversion. The inlay plots the 
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relationship, for each SNP in the inversion region, between the SNP’s significance and its 
squared correlation with the principal component that captures the inversion.
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